[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492133":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":41,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":7,"enrollmentInfo":53,"targetDuration":7,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Piet Pattyn, MD, PhD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+32 9 332 1295","piet.pattyn@ugent.be",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Annouck Philippron, MD","+32 9 332 1531","annouck.philippron@ugent.be",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"University hospital Ghent","RECRUITING","Ghent","Oost-Vlaanderen","9000","Belgium","BE",{"type":31,"coordinates":32},"Point",[33,34],3.71667,51.05,{"lat":34,"lon":33},[37,38],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[42],{"name":43,"class":6},"Universitaire Ziekenhuizen KU Leuven","100492133",false,"NCT05688176","Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Inclusion Criteria:\n\n* Barrett's Esophagus with length \\> 3cm OR esophageal adenocarcinoma histologically proven\n* Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent\n* Age over 18 years\n* No other concurrent malignant disease\n* No inclusion in other clinical trials interfering with the study protocol\n* No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy\n* Absence of any severe organ insufficiency\n* No pregnancy or breast feeding\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Active bacterial, viral or fungal infection\n* Parenchymal liver disease (any stage cirrhosis)\n* High risk of bleeding during biopsy (anticoagulants, esophageal varices)\n* Esophageal squamous cell carcinoma\n* Helicobacter pylori positive at the time of biopsy sampling\n* Radiofrequency ablation of the oesophagus\n* Psychiatric pathology capable of affecting comprehension and judgement faculty",true,"ALL","18 Years",{"count":54,"type":55},100,"ESTIMATED","OBSERVATIONAL","This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.",[59],"Esophageal Neoplasms",[59,61,62],"Liquid biopsy","Transcriptome","2024-07-16",{"date":65,"type":66},"2024-07-17","ACTUAL",{"date":68,"type":7},"2016-06",{"date":70,"type":55},"2027-01-31",{"name":5,"class":6},1]